** Shares of ProKidney PROK.O rise 62.4% to $1.25 cents premarket
** Co says its drug, rilparencel, showed improvement in kidney function decline in patients with chronic kidney disease and diabetes during mid-stage trial
** PROK has upcoming meeting with Food and Drug Administration to confirm approach of drug's planned late-stage trial
** Up to last close, stock down 64% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.